Inhibrx Biosciences (NASDAQ: INBX) net income
Inhibrx Biosciences reported a net loss of $140.1m for fiscal 2025; in fiscal 2024 it reported a net profit of $1,688m. Earnings per share were −$9.04.
Inhibrx Biosciences's best year of the last 3 was fiscal 2024. It reported a loss in 2 of those 3 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | −$140.1m | −108.3% | −10,773.5% | −$9.04 |
| 2024 | $1,688m | — | 843,786.0% | $114.01 |
| 2023 | −$241.4m | — | −13,408.9% | −$20.48 |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Inhibrx Biosciences net income compared with its sector
By net income for its latest fiscal year, Inhibrx Biosciences ranks 370th of the 501 US health care companies with a page on Celsmar. The sector median net margin is −6.2%; that of Inhibrx Biosciences, −10,773.5%.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 368th | Zentalis Pharmaceuticals | −$137.1m | — |
| 369th | Bicara Therapeutics | −$138.0m | — |
| 370th | Inhibrx Biosciences | −$140.1m | −10,773.5% |
| 371st | 4D Molecular Therapeutics | −$140.1m | −164.4% |
| 372nd | Structure Therapeutics | −$141.2m | — |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of Inhibrx Biosciences
- How much did Inhibrx Biosciences earn in fiscal 2025?
- Inhibrx Biosciences reported a net loss of $140.1m for fiscal 2025. In fiscal 2024 it reported a net profit of $1,688m.
- What are the earnings per share of Inhibrx Biosciences?
- They were −$9.04 in fiscal 2025, compared with $114.01 in fiscal 2024.
- What was the most profitable year for Inhibrx Biosciences?
- Of its last 3 fiscal years, fiscal 2024, with $1,688m.
- Where does Inhibrx Biosciences rank in its sector by net income?
- It ranks 370th of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for Inhibrx Biosciences come from?
- From the annual report (Form 10-K) that Inhibrx Biosciences files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Inhibrx Biosciences files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023. More on Inhibrx Biosciences: the Inhibrx Biosciences page · annual accounts · revenue · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.